Increasing unusual option volume: MULN EQNR APLS WEAT CTIC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
CTI BioPharma (CTIC) PT Raised to $12 at Brookline Capital Markets Following FDA Approval
March 1, 2022 10:13 AM ESTBrookline Capital Markets analyst Leah Rush Cann raised the price target on CTI BioPharma (NASDAQ: CTIC) to $12.00 (from $7.20) while maintaining a Buy rating following FDA approval for Pacritinib (Vonjo) in Myelofibrosis.
The analyst commented, "The timing of this FDA-approval is as expected and the prescribing label, with no black box warning and an... More
